x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012297
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human, Mouse, Rat |
| Applications | WB, IP |
| Product Description | Monoclonal antibody is produced by immunizing animals with recombinant protein surrounding Gly870 of human MRP3 protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | ABCC3 |
| UniProt No. | O15438 |
| Gene ID | 8714 |
| Gene Description | MRP3/ABCC3 belongs to the super family of ATP-binding cassette transporters. It is a member of the MRP subfamily that is expressed in various organs including liver, gallbladder, small intestine, colon, kidney, and adrenal gland. MRP3 is involved in multi-drug resistance. It facilitates the efflux of organic anions including monoanionic bile acid and anti-cancer reagents such as etoposide and paclitaxel from liver and small intestine into blood. Expression of MRP3 is increased in the cholestatic human and rat liver, suggesting its role in cholehepatic and enterohepatic bile circulation and in protecting liver from toxic bile salts. MRP3 expression is also upregulated in people with Dubin-Johnson Syndrome who lack functional MRP2 in the liver, which implicates the compensatory role of MRP3 in the absence of functional MRP2.Elevated expression of MRP3 has been detected in various cancer types such as hepatocellular carcinomas, primary ovarian cancer, and adult acute lymphoblastic leukemia. Overexpression of MRP3 was reported to be a prognostic factor in ALL and adult acute myeloid leukemia . |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
